Pancreatic Cancer Clinical Trials in Ohio

Showing 61-80 of 149 trials

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612

The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk), followed by an antiherpetic prodrug, valacyclovir.

Pancreatic AdenocarcinomaPancreatic Cancer

Candel Therapeutics, Inc.27 participantsStarted Aug 2008

Duarte, California, United States • La Jolla, California, United States • Columbus, Ohio, United States

COMPLETEDPhase 355 miles

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00057876

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether gemcitabine is more effective with or without radiation therapy in treating pancreatic cancer. PURPOSE: Randomized phase III trial to study the effectiveness of gemcitabine with or without radiation therapy in treating patients who have locally advanced, unresectable pancreatic cancer.

Pancreatic Cancer

Eastern Cooperative Oncology Group74 participantsStarted Aug 2003

Phoenix, Arizona, United States • Hot Springs, Arkansas, United States • Fresno, California, United States +226 more locations

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Milademetan in Advanced/Metastatic Solid Tumors

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Other Conditions in Ohio